QUARTUCCIO, Luca
 Distribuzione geografica
Continente #
NA - Nord America 11.214
EU - Europa 3.089
AS - Asia 1.359
AF - Africa 43
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 15.724
Nazione #
US - Stati Uniti d'America 11.156
UA - Ucraina 1.039
SG - Singapore 532
CN - Cina 498
IT - Italia 461
DE - Germania 458
FI - Finlandia 287
IE - Irlanda 236
SE - Svezia 195
RU - Federazione Russa 164
TR - Turchia 139
GB - Regno Unito 121
VN - Vietnam 80
CA - Canada 57
IN - India 41
FR - Francia 24
IR - Iran 24
CZ - Repubblica Ceca 23
TG - Togo 20
BE - Belgio 19
EG - Egitto 14
JP - Giappone 14
NL - Olanda 14
HK - Hong Kong 13
PL - Polonia 12
ES - Italia 7
EU - Europa 6
KR - Corea 6
RO - Romania 5
AR - Argentina 4
AT - Austria 4
CL - Cile 4
EE - Estonia 4
PT - Portogallo 4
MA - Marocco 3
TW - Taiwan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CH - Svizzera 2
GR - Grecia 2
IL - Israele 2
AU - Australia 1
BO - Bolivia 1
BR - Brasile 1
ET - Etiopia 1
HR - Croazia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LT - Lituania 1
LV - Lettonia 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
ZM - Zambia 1
Totale 15.724
Città #
Woodbridge 1.633
Ann Arbor 1.122
Fairfield 1.060
Houston 952
Chandler 767
Jacksonville 678
Ashburn 527
Wilmington 519
Seattle 431
Singapore 426
Dearborn 414
Boardman 348
Cambridge 335
Dublin 233
Beijing 232
Princeton 229
Udine 171
Izmir 137
Dong Ket 80
San Diego 78
Des Moines 60
Ogden 60
Norwalk 50
Ottawa 41
Redmond 41
Nanjing 36
Hefei 29
Munich 29
Trieste 27
San Mateo 26
Brno 21
Los Angeles 21
Milan 21
Lomé 20
New York 20
Brussels 18
Santa Clara 16
Auburn Hills 15
Falls Church 15
Kunming 15
Rome 15
Dallas 14
Guangzhou 14
Helsinki 14
London 14
Toronto 14
Augusta 12
Grafing 11
Leawood 11
Simi Valley 11
Warsaw 11
Amsterdam 10
Chengdu 10
Lappeenranta 10
Saint Louis 10
Shanghai 10
Ardabil 9
Hong Kong 9
Hyderabad 9
Nanchang 9
Phoenix 9
Jinan 8
Redwood City 8
Shenzhen 8
Wuhan 8
Frankfurt am Main 7
Mumbai 7
Fuzhou 6
Monmouth Junction 6
Paris 6
Shenyang 6
Tavagnacco 6
Verona 6
Xian 6
Andover 5
Edinburgh 5
Hangzhou 5
Jiaxing 5
Maserada Sul Piave 5
Turin 5
Washington 5
Baotou 4
Cagliari 4
Chicago 4
Codroipo 4
Indiana 4
New Orleans 4
Tallinn 4
Tappahannock 4
Vicenza 4
Albolote 3
Buffalo 3
Cairo 3
Florence 3
Harbin 3
Menlo Park 3
Pisa 3
Quzhou 3
Ravenna 3
Rosario 3
Totale 11.378
Nome #
Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. 156
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 153
Pain management in cryoglobulinaemic syndrome 142
Validation of the classification criteria for cryoglobulinaemic vasculitis. 141
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 140
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 140
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 138
Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. 132
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome 131
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides. 128
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis 127
Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs 126
Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. 125
Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands 125
Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. 125
Use of teriparatide in osteoporosis due to active rheumatic diseases 124
Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients 124
Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis 121
Pachydermodactyly: The role of ultrasonography and dermoscopy for diagnosis 120
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. 120
Gitelman syndrome disclosed by calcium pyrophosphate deposition disease: Early diagnosis by ultrasonographic study 119
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 119
BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands 118
AB0695 Anti-prothrombin/phosphatidyl-serine complex autoantibodies in antiphospholipid syndrome: Preliminary data using a new ELISA method 118
Patient-reported impact of spondyloarthritis on work disability and working life: The ATLANTIS survey 118
Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients 118
Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies 116
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. 116
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis 114
Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. 114
Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution 114
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 114
Role e of oral cyclophosphamide in the treatment of giant cell arteritis 113
Accuracy of Computer-Guided Flapless Implant Surgery in Fully Edentulous Arches and in Edentulous Arches With Fresh Extraction Sockets 112
Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus 112
Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection 111
Classification of cryoglobulinemic vasculitis 109
Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. 109
Efficacy of intravenous cyclosporine in a case of cytophagic histiocytic panniculitis complicated by haemophagocytic syndrome after visceral leishmania infection 109
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis 108
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis 107
A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) 106
Gastrointestinal Involvement in Systemic Vasculitis 106
L. Quartuccio, M. Fabris, M. Maset, E. Pontarini, A. Zabotti, S. De Vita Bone marrow b-cell expansion in mixed cryoglobulinemia: association with nephritis and response to rituximab 105
Treatment of rheumatoid arthritis with rituximab: an update and possible indications. 105
Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al 104
Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis 103
B lymphocyte stimulator (BLyS) and monocytes: possible role in autoimmune diseases with a particular reference to rheumatoid arthritis 102
Strontium ranelate and femural fracture healing during rheumatoid arthritis and osteoporosis 102
Mycophenolic Acid AUC estimation in patients with lupus nephritis using an algorithm validated in an heart transplanted population 100
A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation 99
Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome 99
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. 99
Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer 99
Variations in lumbar and femural bmd after rituximab therapy in active rheumatoid arthritis 98
A randomized controlled trial of rituximab for treatment of severe cryoglobulinemic vasculitis. 97
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC) 97
A randomized, controlled, multicenter phase iii study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) Ann Rheum Dis 2010;69(Suppl3):93 96
Preliminary classification criteria for the cryoglobulinaemic vasculitis 95
Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. 95
efficacy of methotrexate in polymyalgia rheumatica 93
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. 92
Delayed Positivization of Cerebral Angiography in Reversible Cerebral Vasoconstriction Syndrome (RCVS) Presenting with Recurrent Subarachnoid Haemorrhage. 92
Pleuritis is a red flag for Adult-onset Still's disease which may require biologic therapies. 91
Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. 91
Pregnancy and fetal outcome in patients with an established diagnosis of primary sjögren's syndrome 90
Myositis in primary sjögren's syndrome: data from a multicenter cohort 90
Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study 90
Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. 89
Safety of Rituximab in different rheumatic autoimmune diseases. A single centre experience in 85 cases. 2008 88
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study 88
The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis 88
High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with Sjögren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. 87
Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients 87
Fetal Outcome in Patients with an Established Diagnosis of Primary Sjögren’s Syndrome 85
B-Lymphocyte Stimulator (BLyS) in mixed cryoglobulinemia sindrome: pathobiological and clinical implication 85
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 85
prevalence of chlamydophila psittaci subclinical infection in italian patients with rheumatoid arthritis: etiopathological and therapeutic implications 83
Primary sjögren's syndrome as a multi-organ disease: Impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients 83
A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy 82
Rheumatoid factor positivity, a lower disability and a lower number of anti-tnf agents failed are associated with response to rituximab in rheumatoid arthritis 82
Articular and peripheral nervous system involvement are linked to the long-term outcome in primary Sjögren's syndrome: The relevance of single organ manifestations rather than a composite score as predictors 82
Rituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinaemia 81
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 81
A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. 80
The role of the il-6 promoter p in predicting rituximab efficacy in rheumatoid artolymorphism 80
Fibronectin gene polymorphisms and clinical manifestations of mixed cryoglobulinemic syndrome: increased risk of lymphoma associated to MspI DD and HaeIII AA genotypes 80
Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients 80
Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis 80
Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review 79
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjo¨gren’s Syndrome: Results of the Beliss Study. 78
Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. 77
Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue 77
Gastrointestinal involvement in systemic vasculitis 77
Association be tween B cell clonal expansion and glomerulonephritis in type cryoglobulinnaemia. 2007; 66 (Suppl. II): 121 76
Ciclosporina e tacrolimus nella miosite da corpi inclusi: efficacia clinica, sicurezza e risparmio nell'uso dei corticosteroidi 76
Clinical characterization and treatment outcome in a monocentric cohort of 45 patients with adult onset still's disease. 76
Rituximab in mixed cryoglobulinemia: increased experience and perspectives 76
Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus 75
Long-term response to rituximab in 36 patents with the reumatoid arthritis: a single centre wxperience. 74
Totale 10.259
Categoria #
all - tutte 69.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.724


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.306 0 0 0 0 0 585 401 412 254 319 91 244
2020/20212.489 78 270 52 274 103 275 67 258 527 84 325 176
2021/20221.678 62 173 89 138 44 48 91 109 25 235 369 295
2022/20232.035 248 95 38 221 208 544 35 147 296 38 77 88
2023/2024763 109 62 29 19 144 89 30 64 99 60 21 37
2024/20251.350 121 403 231 158 236 201 0 0 0 0 0 0
Totale 16.540